RohitLoombaMDMHSc

PubMed

• 163 citations
  A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
  Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba
  The New England Journal of Medicine. 2024-02-08
• 90 citations
  Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase I...
  Naim Alkhouri, Robert Herring, Heidi Kabler, Zeid Kayali, Tarek Hassanein
  Journal of Hepatology. 2022-09-01
• 33 citations
  Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.
  Michail Kokkorakis, Chrysoula Boutari, Michael A Hill, Vasilios Kotsis, Rohit Loomba
  Metabolism. 2024-05-01

Journal Articles

• The Lancet Child & Adolescent Health  
  Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
• Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis  
  Rohit Loomba, Ariel E Feldstein, The Journal of Immunology
• Author Correction: Inflammation-Induced IgA+ Cells Dismantle Anti-Liver Cancer Immunity  
  Rohit Loomba, MD, Nature
• Inter-Sonographer Reproducibility of Quantitative Ultrasound Outcomes and Shear Wave Speed Measured in the Right Lobe of the Liver in Adults with Known or Suspected No...  
  Claude B Sirlin, Rohit Loomba, European Radiology
• Novel Plasma Biomarkers Associated with Liver Disease Severity in Adults with Nonalcoholic Fatty Liver Disease  
  Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat B; NASH Clinical Research Network., Hepatology, 1/1/2017
• Identifying NAFLD Patients with Active Fibrosis by Measuring Extracellular Matrix Remodeling Rates in Tissue and Blood  
  Decaris ML, Li KW, Emson CL, Gatmaitan M, Liu S, Wang Y, Nyangau E, Colangelo M, Angel TE, Beysen C, Cui J, Hernandez C, Lazaro L, Brenner DA, Turner SM, Hellerstein M..., Hepatology, 1/1/2017
• Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging  
  Lin SC, Heba E, Bettencourt R, Lin GY, Valasek MA, Lunde O, Hamilton G, Sirlin CB, Loomba R, Aliment Pharmacol Ther., 1/1/2017
• A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty ...  
  Paige JS, Bernstein GS, Heba E, Costa EA, Fereirra M, Wolfson T, Gamst AC, Valasek MA, Lin GY, Han A, Erdman JW Jr, O'Brien WD Jr, Andre MP, Loomba R, Sirlin CB., AJR, 1/1/2017
• Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis  
  Kim RG, Loomba R, Prokop LJ, Singh S., Clin Gastroenterol Hepatol., 1/1/2017
• Magnitude and Kinetics of Decrease in Liver Stiffness After Anti-viral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis  
  Singh S, Facciorusso A, Loomba R, Falck-Ytter YT., Clin Gastroenterol Hepatol., 1/1/2017
• Increased Risk of Death, in the Hospital and Outside the Intensive Care Unit, for Patients With Cirrhosis After Cardiac Arrest  
  Reinders ME, Wardi G, Bettencourt R, Bouland D, Bazick J, Mendler M, Vodkin I, Kalmaz D, Savides T, Brenner D, Sell RE, Loomba R., Clin Gastroenterol Hepatol., 1/1/2017
• Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study  
  Barritt AS Th, Gitlin N, Klein S, Lok AS, Loomba R, Malahias L, Powell M, Vos MB, Weiss LM, Cusi K, Neuschwander-Tetri BA, Sanyal A, Contemp Clin Trials., 1/1/2017
• Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification  
  Hong CW, Wolfson T, Sy EZ, Schlein AN, Hooker JC, Fazeli Dehkordy S, Hamilton G, Reeder SB, Loomba R, Sirlin CB, J Magn Reson Imaging., 1/1/2017
• MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis  
  Hong CW, Mamidipalli A, Hooker JC, Hamilton G, Wolfson T, Chen DH, Fazeli Dehkordy S, Middleton MS, Reeder SB, Loomba R, Sirlin CB., J Magn Reson Imaging., 1/1/2017
• Genome-Wide Associations Related to Hepatic Histology in Nonalcoholic Fatty Liver Disease in Hispanic Boys  
  Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YI, Goodarzi MO, Taylor KD, Yates KP, Tonascia J, Rotter JI., J Pediatr., 1/1/2017
• Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients with Non-alcoholic Liver Disease  
  Caussy C, Chen J, Alquiraish MH, Cepin S, Nguyen P, Hernandez C, Yin M, Bettencourt R, Cachay ER, Jayakumar S, Fortney L, Hooker J, Sy E, Valasek MA, Rizo E, Richards ..., Clin Gastroenterol Hepatol., 1/1/2017
• Editorial: non-alcoholic fatty liver disease-a pandemic in need of novel treatments and endpoints  
  Ajmera V, Loomba R., Aliment Pharmacol Ther., 1/1/2017
• Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant dat...  
  Singh S*, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN, Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL, Euro Radiology., 1/1/2016
• Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE  
  Doycheva I*, Cui J*, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R, Aliment Pharmacol Ther, 1/1/2016
• Practice patterns in NAFLD and NASH: Real life differs from published guidelines  
  Rinella ME, Lominadze Z, Loomba R, Charlton M, Neuschwander-Tetri BA, Caldwell SH, Kowdley K and Harrison SA., Therapeutic Advances in Gastroenterology, 1/1/2016
• MRE is superior to ARFI for the diagnosis of fibrosis in patients with biopsy- proven NAFLD: A prospective study  
  Cui J*, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, Valasek MA, Aryafar H, Sirlin CB, Loomba R., Hepatology, 1/1/2016
• Targeting Dysbiosis for the Treatment of Liver Disease  
  Anand G*, Zarrinpar A, Loomba R., Semin Liver Dis., 1/1/2016
• Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients  
  Ray Kim W, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, Janssen HL, Lampertico P, Lau D, Bornstein JD, Aguilar Schall RE, Dinh P, Yee LJ, Martins EB, Lim SG, Loomb..., Journal of Hepatology, 1/1/2016
• Review: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis  
  Noureddin M, Anstee QM, Loomba R., Aliment Pharmacol Ther., 1/1/2016
• Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective study  
  Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt, Wang K, Aryafar H, Behling C, Valasek MA, Lin GY, Gamst A, Brenner DA, Yin M, Glaser KJ, Ehm..., Am J Gastronterol., 1/1/2016
• Join now to see all

Abstracts/Posters

• Treatment with selonsertib, an inhibitor of apoptosis signal regulating kinase 1, hepatic phospho-p38 expression and markers of hepatocellular apoptosis and necrosis i...
  Diehl A.M., French D, Xu R, Loomba R, Lawitz E, Freilich B, Shiffman M.L., Chalasani N, Hameed B, Caldwell S, Rinella M, Peach M, Huntzicker E, Turner S, Sullivan T, C..., EASL, 1/1/2017
• Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes (PROS)
  Younossi Z.M., Stepanova M, Goodman Z, Lawitz E, Charlton M, Loomba R, Hunt S., EASL, 1/1/2017
• Methylation signatures in blood show accelerated epigenetic aging in patients with non-alcoholic steatohepatitis compared to healthy controls.
  Loomba R, Gindin Y, Jiang Z, Lawitz E, Djedjos C.S., Caldwell S, Xu R, Gong D, Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Afdhal N.H., A.M. Diehl A.M., EASL, 1/1/2017
• Comparison of clinical prediction rules for detection of cirrhosis in non-alcoholic fatty liver disease: a multicenter, international, collaborative study- NASH CRN (U...
  Brandman, Boyle M, McPherson S, Van Natta M, Sanyal A, Kowdley K, Tetri B, Chalassani N, Abdelmalek M, Terrault N.A., McCullough A, Bettencourt R, Caussy C. Kleiner D,..., EASL, 1/1/2017
• BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study.
  Sanyal1 A, Charles E.D., Neuschwander-Tetri B, Loomba R, Harrison S, Abdelmalek M, Lawitz E, Halegoua-DeMarzio D, Dong Y, Noviello S, Krishnamoorthy S, Luo Y, Christia..., EASL, 1/1/2017
• Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients.
  Turner A, Stolk J, Bals R, Lickliter J, Hamilton J, Christianson D, Given B, Burdon J, Loomba R, Stoller J, Teckman J., EASL, 1/1/2017
• NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, pl...
  Harrison S.A., Abdelmalek M.F., Trotter J.F., Paredes A.H., Arnold H.L., Kugelmas M, Bashir M.R, Ling L, Rossi S.J., DePaoli A.M., Rinella M.E., Loomba R., EASL, 1/1/2017
• Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholi...
  Park C.C., Nguyen P, Hernandez C, Bettencourt R, Ramirez K.S., Fortney L, Hooker J, Sy E., Alquiraish M.H., Valasek M.A., Rizo E, Richards L, Brenner D, Sirlin C, Loom..., EASL, 1/1/2017
• Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steat...
  Middleton M.S., Lawitz E, Jayakumar S, Mantry P, Caldwell S, Diehl A.M., Peach M, Xu R, Chen G, Djedjos C.S., Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Afdh..., EASL, 1/1/2017
• Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in non...
  Loomba R, Lawitz E, Ghalib R, Elkhashab M, Caldwell S, Abdelmalek M, Kowdley K, Xu R, Chen G, Djedjos C.S., Myers R.P., Subramanian G.M., Goodman Z, Charlton M, Sirlin..., EASL, 1/1/2017
• Hepatic Proton Density Fat Fraction Correlates with Histologic Measure of Steatosis and is Responsive To Change in Those Measures in a Multi-Center Nonalcoholic Steato...
  Loomba R, Lawitz E, Jayakumar S, Mantry P, Caldwell S, Diehl AM, Peach M, Xu R, Djedjos CS, Natha M, Myers M, Subramanian M, Goodman Z, Charlton M, Afdhal N, Sirlin C,..., DDW, 1/1/2017
• Transient Elastography in Detection of Fibrosis and Noninvasive measurement of Steatosis in patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
  Park C, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Alquiraish M, Valasek M, Rizo E, Richards L, Brenner D, Sirlin C, Loomba R. Magneti..., DDW, 1/1/2017
• Reduced Coenzyme Q10 Levels Are Associated with Advanced Fibrosis in Adults With Nonalcoholic Steatohepatitis.
  Kemme S, Miles M, Loomba R, Xanthakos S, Kohli R, DDW, 1/1/2017
• Association of Nonalcoholic Fatty Liver Disease with Visceral Adiposity but not Coronary Artery Calcification in the Elderly
  Jacobs K, Brouha S, Bettencourt R, Barrett-Connor E, Sirlin C, and Loomba R, DDW, 1/1/2016
• Comparative Efficacy and Tolerability of Long-Term Pharmacological Interventions for Obesity: A Systematic Review and Network Meta-Analysis
  Loomba R., DDW, 1/1/2016
• Shared Genetic Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study.
  Loomba R, DDW, 1/1/2016
• Sitagliptin versus Placebo in the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial.
  Loomba R, DDW, 1/1/2016
• Effect of weight loss on MRE Estimated Stiffness in Patients with Nonalcoholic Fatty Liver Disease.
  Loomba R, DDW, 1/1/2016
• Serum microRNA Profiling Differentiates NASH and Advanced Fibrosis in Well Characterized Patients with Biopsy-Proven NAFLD
  Loomba R, DDW, 1/1/2016
• Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements with Obeticholic Acid
  Loomba R, DDW, 1/1/2016
• Magnetic Resonance Elastography Identifies Fibrosis in Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Pilot Prospective Study
  Loomba R, DDW, 1/1/2016
• Predictors of Improvement in NAFLD Activity Score on Placebo: A Secondary Analysis of the FLINT Trial.
  Loomba R, Sanyal A.J, Kowdley K.V, Terrault N, Chalasani N.P, Abdelmalek M.F, McCullough A.J, Ferguson B, Lee L, Shringarpure R, Shapiro D, and Neuschwander-Tetri B.A., EASL, 1/1/2016
• Sitagliptin Verses Placebo in the Treatment of Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
  Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hookeer J, Haufe W, Hooker C, Brenner D.A, Sirlin C.B, and Loomba R, EASL, 1/1/2016
• Genome- Wide Association Study of Clinically Significant Portal Hypertension in Patients With Alcoholic Steatohepatitis and Advanced Fibrosis
  Shea P.R, Sanyal A, Rockey D.C, Loomba R, Diehl A.M, Kleinstein S.E, Myers R.P, Mani Subramanian G, McHutchison J.G, Abdelmalek M.F, Ratzui V, Afdhal N, Harrison S, Bo..., EASL, 1/1/2016
• Shared Gene Effects Between Hepatic Steatosis and Fibrosis: A Prospective Twin Study.
  Cui J, Chen C-H, Lo M-T, Schork N, Bettencourt R, Bhatt A, Hooker J, Nelson K.E, Long M.T, Brenner D.A, Sirlin C.B, and Loomba R., EASL, 1/1/2016
• Join now to see all

Lectures

• Novel Imaging and Management of NASH 
  1/1/2017
• Imaging assessment of NAFLD 
  Northwestern University, Chicago, IL - 1/1/2016
• Novel phenotyping and imaging advances in NAFLD 
  Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH) - 1/1/2016
• Innovations in clinical trial design and novel imaging in NAFLD 
  Brook Army Medical Center, San Antonio - 1/1/2015
• Emerging and standard therapies for alcoholic hepatitis and NASH 
  Chicago, IL - 1/1/2015
• Emerging therapies for NASH 
  Scripps Clinic, La Jolla, CA - 1/1/2015
• I just diagnosed NAFLD what do I do now? 
  Miami, FL - 1/1/2015
• Magnetic resonance Imaging and transient elastography in the assessment of liver disease 
  University of Michigan, Ann Arbor, MI - 1/1/2014
• Key issues in NASH trials 
  University of Michigan, MI - 1/1/2014
• Key clinical issues in the assessment of nonalcoholic fatty liver disease 
  Mayo Clinic, Rochester, MN - 1/1/2014
• The Diagnostic Challenge of Non-Alcoholic Fatty Liver Disease--Role of Plasma Biomarkers, Imaging, and Liver Biopsy 
  San Francisco, CA - 1/1/2014
• Turning points in CHB patient care: how far can we go? 
  Jeju, Korea - 1/1/2014
• Key clinical issues in the management of nonalcoholic fatty liver disease 
  La Jolla, CA - 1/1/2014
• Similarities and differences in ASH and NASH 
  Chicago, IL - 1/1/2014
• Novel therapies for hepatitis B 
  Brisbane, Australia - 1/1/2014
• Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases 
  1/1/2014
• First Line Therapy or Waiting for Something Better? 
  1/1/2013
• Changing the management paradigm in NAFLD 
  University of Alabama, Birmingham - 1/1/2013
• Non-invasive biomarkers of NAFLD 
  Orlando - 1/1/2013
• How to predict treatment response in NASH? 
  Orlando - 1/1/2013
• Management of NAFLD 
  Hyderabad, India - 1/1/2013
• Solid organ transplant in elderly 
  1/1/2012
• Epidemiology of NAFLD 
  University of California, Irvine - 1/1/2012
• Changing the management paradigm in NASH 
  Guwahati, India - 1/1/2012
• Synergistic Effect of Alcoholc and Obesity on Liver Disease 
  Stockholm, Sweden - 1/1/2011
• Join now to see all